Before you sell to, join or invest in Esanik Therapeutics, Inc.
MentionFox check on Esanik Therapeutics, Inc.: only 1 source on file so far (checked 8 November 2026). Run a full check before you rely on it. mentionfox.com/c/funding/esanik-therapeutics-inc-form-d-24000001
Check Esanik Therapeutics, Inc. before you sell to, join or invest Free, no sign-up: every record on file, each linked to its source.
Esanik Therapeutics, Inc. filed a Form D with the Securities and Exchange Commission on 2024-11-14.
Esanik Therapeutics, Inc. filed a Form D notice of an exempt securities offering with the SEC on November 14, 2024. The filing reports $3.28M sold. Its industry group is Pharmaceuticals. It names John Sorensen (Executive Officer) (SEC Form D, November 14, 2024).
Is this your company?
125 companies raised this week.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| Andersen Aggregator LLC | $1.9B | Business services |
| AT Umbrella LLC | $1.9B | Business services |
| Legora, Inc. | $221M | AI and software |
| MD INVESTMENT LLC | $169M | Business services |
| Serval Inc. | $149M | AI and software |
Sell to companies like Esanik Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2024-11-14 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Esanik Therapeutics, Inc.
Free to see. No signup.
Get an email when Esanik Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Esanik Therapeutics, Inc. raises, hires or launches. No email unless you switch it on.
Watch Esanik Therapeutics, Inc. →Get the full cited report on Esanik Therapeutics, Inc.
What the filing shows about Esanik Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Esanik Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Esanik Therapeutics, Inc.'s address as 7 Rapps Run Drive, Malvern, PA 19355.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for Esanik Therapeutics, Inc. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Esanik Therapeutics, Inc. See pricing
Esanik Therapeutics, Inc. is a registered filer with the SEC (CIK 2044524) and has filed since 2024-11-14. 2 filings are on record, the latest on 2026-04-30.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Esanik Therapeutics, Inc.'s Form D of 2024-11-14 names John Sorensen as its officers, directors or promoters.
Its new offerings report $3.48M sold across 2 offerings, as its own filings state.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 155 filings in Pharmaceuticals, totalled by week.
Other than the payment of salaries and other compensation and benefits and reimbursement expenses, no officer, director, partner, manager or promoter will receive any payments from the proceeds of this offering.
John Sorensen is named as Executive Officer on the Form D that Esanik Therapeutics, Inc. filed with the SEC on 14 November 2024, the only person that filing names.
1 person named on the filing — 1 holding an executive role.
Named as of the 2024-11-14 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
What the filing shows about Esanik Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Esanik Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Esanik Therapeutics, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Esanik Therapeutics, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Esanik Therapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Esanik Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Pharmaceuticals raises in Philadelphia
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/esanik-therapeutics-inc-form-d-24000001